GLUCOTRACK INC (GCTK)
NASDAQHealth CareMedical - DevicesSnapshot 2026-10-29
$1.39-32.20%
Close 2026-10-29 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-10-29
Research Workspace
Put GCTK beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Supplies is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Reduce negative cash flow from operations: Comparison needs review.
View ThesisManagement screens weak on capital allocation, margins, market reaction to earnings.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 6% on a typical day and fell roughly 100% in its worst 12-month stretch.
View RiskGCTK’s case rests on stronger finances, despite unsteady management and high risk. Revenue growth and earnings trends remain unknown; no earnings release is recorded. Warrant changes and bridge-note repayment strengthen its finances. A public offering may dilute shares and affect finances. Peer multiples and priced-in expectations are unavailable, so valuation cannot be assessed. Negative operating cash flow is a concern, but the comparison needs review. No next-quarter miss probability is available. Our standing thesis is on watch; this read is provisional.
Trailing returns as of 2026-10-29. GCTK is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Continue this research
Compare GCTK with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| GCTK Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Supplies — fair value, gap to price, and forward P/E.
Compare the value case
Put GCTK next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Strengthen financial position and manage capital allocation
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Strengthens financial position through debt repayment and agreement amendments.
Threatens: Strengthen financial position and manage capital allocation
Public offering may dilute shares and affect financial position.
Director's resignation may impact management stability and execution.
Advances: Strengthen financial position and manage capital allocation
Financing strengthens financial position and capital allocation.
Threatens: Strengthen financial position and manage capital allocation
Reverse split may affect investor confidence and financial position.
Milestone supports commercialization and revenue generation.